A Revolutionary Diabetes Drug You Need to Watch

Novo Nordisk's new diabetes drug could offer patients a more convenient way to take insulin, but development will take a few more years.

Max Macaluso
Max Macaluso
Mar 21, 2013 at 4:07PM
Health Care

Bloomberg recently reported that pharmaceutical company Novo Nordisk (NYSE:NVO), in collaboration with a small biotech company called Merrion Pharmaceuticals, recently completed a phase 1 study for an oral insulin drug. The experimental medication, known only as NN1954, could help the company's revenue grow over the long term if it eventually gains approval. However, Motley Fool health care analyst Max Macaluso believes that investors shouldn't get too excited about this news just yet. Watch the following video to find out why and how Novo Nordisk's project may one day become a threat to Sanofi's (NASDAQ:SNY) mega-blockbuster insulin drug Lantus.